| NMUEX | RWEBX | NMUEX / RWEBX | |
| Total Expense Ratio | 0.13 | 1.06 | 12% |
| Annual Report Gross Expense Ratio | 0.73 | 1.06 | 69% |
| Fund Existence | 5 years | 12 years | - |
| Gain YTD | 6.615 | 3.422 | 193% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 0 | 250 | - |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 251M | 219B | 0% |
| Annual Yield % from dividends | 0.52 | 0.76 | 68% |
| Returns for 1 year | 13.43 | 4.91 | 273% |
| Returns for 3 years | 23.33 | 26.14 | 89% |
| Returns for 5 years | N/A | 24.05 | - |
| Returns for 10 years | N/A | 70.82 | - |
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| TEQI | 51.34 | 0.15 | +0.29% |
| T. Rowe Price Equity Income ETF | |||
| USMC | 74.63 | N/A | N/A |
| Principal US Mega-Cap ETF | |||
| IBBQ | 33.09 | N/A | N/A |
| Invesco Nasdaq Biotechnology ETF | |||
| LQTI | 18.95 | -0.08 | -0.45% |
| FT Vest Investment Grade & Target Income ETF | |||
| VYLD | 29.74 | -0.16 | -0.52% |
| Inverse Vix Short-Term Futures Etns Due March 22, 2045 | |||